Thursday, July 9, 2026

Patent intelligence · US

US 10195259

Compositions and methods for treatment of cancer using bacteria

granted A61KA61K2039/521A61K2039/522A61K2039/523
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 13
Applicant portfolio 6
Patent details — US 10195259
Jurisdiction
US
Status
granted
Grant date
Feb 5, 2019
Expiration
Jan 31, 2039
Claims
10
CPC classes
A61K, A61K2039/521, A61K2039/522, A61K2039/523
View on Google Patents ↗

Quick answer

US 10195259 (Compositions and methods for treatment of cancer using bacteria) is held by Decoy Biosystems, Inc.. Status: granted. Granted Feb 5, 2019. Expires Jan 31, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
10
CPC classes
A61K, A61K2039/521, A61K2039/522, A61K2039/523, A61K2039/585, A61K31/11

More from Decoy Biosystems, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12226474

    Methods and compositions for treating infections

    Decoy Therapeutics Inc. · Expires Feb 13, 2045

    granted
  2. US 11147844

    Methods of treatment of infections using bacteria

    Decoy Biosystems, Inc. · Expires Oct 14, 2041

    granted
  3. US 11045504

    Compositions and methods for treatment of cancer using bacteria

    Decoy Biosystems, Inc. · Expires Jun 24, 2041

    granted
  4. US 10052371

    Compositions and methods for treatment of cancer using bacteria

    Decoy Biosystems, Inc. · Expires Aug 16, 2038

    granted
  5. US 9265804

    Compositions and methods for treatment of cancer using bacteria

    Decoy Biosystems, Inc. · Expires Feb 18, 2036

    granted

Frequently asked questions

What is US patent 10195259?

US 10195259 (Compositions and methods for treatment of cancer using bacteria) is held by Decoy Biosystems, Inc.. Status: granted. Granted Feb 5, 2019. Expires Jan 31, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 10195259?

Decoy Biosystems, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 6 pharmaceutical patents for this assignee.

When does US 10195259 expire?

Our index shows an expiration date of Jan 31, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.